CLEVELAND, Ohio — The World Health Organization considers Acute Respiratory Distress Syndrome, or “ARDS,” to be the leading cause of death among COVID-19 infected patients.
A Cleveland-based biotechnology company is holding clinical trials to see if its stem cell therapy could help COVID-19 induced ARDS patients.
Since 1995, Athersys has worked on developing medicines that could fill unmet medical needs to treat the sickest critical care patients.
Click here to read the complete story.
Story excerpt provided by Spectrum News1.
Written by Micaela Marshall.
Originally published September 11, 2020.